

# Tateaki Naito

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9118982/publications.pdf>

Version: 2024-02-01

221  
papers

5,990  
citations

94381

37  
h-index

95218

68  
g-index

231  
all docs

231  
docs citations

231  
times ranked

7057  
citing authors

#	ARTICLE	IF	CITATIONS
1	Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX $\alpha$ DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. <i>Respirology</i> , 2008, 13, 452-460.	1.3	570
2	Cumulative incidence of and predictive factors for lung cancer in IPF. <i>Respirology</i> , 2009, 14, 723-728.	1.3	249
3	Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. <i>Respiratory Medicine</i> , 2009, 103, 846-853.	1.3	202
4	The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1242-1246.	0.5	177
5	Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 512-519.	0.5	166
6	Interstitial lung diseases associated with amyopathic dermatomyositis. <i>European Respiratory Journal</i> , 2006, 28, 1005-1012.	3.1	151
7	Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System. <i>PLoS ONE</i> , 2013, 8, e67466.	1.1	151
8	Anamorelin (ONO $\alpha$ 7643) for the treatment of patients with non $\alpha$ small cell lung cancer and cachexia: Results from a randomized, double $\alpha$ blind, placebo $\alpha$ controlled, multicenter study of Japanese patients (ONO $\alpha$ 7643 $\alpha$ 04). <i>Cancer</i> , 2018, 124, 606-616.	2.0	147
9	Biologic Correlation of 2- <sup>18</sup> F-Fluoro-2-Deoxy-D-Glucose Uptake on Positron Emission Tomography in Thymic Epithelial Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 3746-3753.	0.8	143
10	Higher Sensitivity and Specificity for Diffusion-weighted Imaging of Malignant Lung Lesions without Apparent Diffusion Coefficient Quantification. <i>Radiology</i> , 2009, 252, 247-254.	3.6	142
11	Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. <i>Supportive Care in Cancer</i> , 2015, 23, 1699-1708.	1.0	129
12	Efficacy of gefitinib for non $\alpha$ adenocarcinoma non $\alpha$ small $\alpha$ cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports. <i>Cancer Science</i> , 2011, 102, 1032-1037.	1.7	128
13	Pulmonary Pleomorphic Carcinoma: A Clinicopathological Study Including EGFR Mutation Analysis. <i>Journal of Thoracic Oncology</i> , 2010, 5, 460-465.	0.5	107
14	Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non $\alpha$ small $\alpha$ cell lung cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 73-83.	2.9	106
15	A multicenter, open $\alpha$ label, single $\alpha$ arm study of anamorelin (ONO $\alpha$ 7643) in advanced gastrointestinal cancer patients with cancer cachexia. <i>Cancer</i> , 2019, 125, 4294-4302.	2.0	99
16	Microcavity Array System for Size-Based Enrichment of Circulating Tumor Cells from the Blood of Patients with Small-Cell Lung Cancer. <i>Analytical Chemistry</i> , 2013, 85, 5692-5698.	3.2	89
17	Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. <i>Lung Cancer</i> , 2011, 74, 457-461.	0.9	80
18	Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. <i>Lung Cancer</i> , 2010, 67, 194-197.	0.9	79

#	ARTICLE	IF	CITATIONS
19	Rebiopsy for patients with non-small cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor failure. <i>Cancer Science</i> , 2016, 107, 1001-1005.	1.7	78
20	Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 891-899.	1.1	77
21	Impaired Toll-like Receptor 9 Expression in Alveolar Macrophages with No Sensitivity to CpG DNA. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 707-713.	2.5	69
22	Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 68, 99-104.	0.9	64
23	Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 2352-2363.	1.2	62
24	Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 521-526.	1.1	62
25	Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. <i>Lung Cancer</i> , 2010, 68, 438-445.	0.9	52
26	Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. <i>BMC Cancer</i> , 2017, 17, 571.	1.1	51
27	LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. <i>American Journal of Translational Research (discontinued)</i> , 2011, 3, 468-78.	0.0	51
28	Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study. <i>BMC Cancer</i> , 2017, 17, 800.	1.1	46
29	High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy. <i>Annals of Oncology</i> , 2017, 28, 669-670.	0.6	44
30	Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 3741-3747.	0.7	44
31	Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 604-613.	0.4	44
32	Long-term survivors of more than 5 years in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 67, 120-123.	0.9	43
33	A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. <i>BMC Cancer</i> , 2019, 19, 528.	1.1	43
34	Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. <i>BMC Cancer</i> , 2013, 13, 354.	1.1	42
35	The Impact of Clinical Outcomes According to EGFR Mutation Status in Patients with Locally Advanced Lung Adenocarcinoma Who Received Concurrent Chemoradiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 144-147.	0.6	41
36	Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. <i>BMC Cancer</i> , 2016, 16, 864.	1.1	41

#	ARTICLE	IF	CITATIONS
37	Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e247-e252.	1.1	41
38	A Validation and Potential Modification of the Pneumonia Severity Index in Elderly Patients with Community-Acquired Pneumonia. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1212-1219.	1.3	39
39	Biologic correlates of 18F-FDG uptake on PET in pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2011, 71, 144-150.	0.9	38
40	Multiplexed Molecular Profiling of Lung Cancer Using Pleural Effusion. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1048-1052.	0.5	36
41	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. <i>Cancer Science</i> , 2018, 109, 2539-2548.	1.7	35
42	Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. <i>Anticancer Research</i> , 2012, 32, 1103-6.	0.5	34
43	Molecular profiling of small cell lung cancer in a Japanese cohort. <i>Lung Cancer</i> , 2014, 84, 139-144.	0.9	32
44	Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 432-433.	0.5	32
45	Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation. <i>Annals of Oncology</i> , 2014, 25, 1948-1953.	0.6	31
46	Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 989.	1.1	31
47	Promotion of Behavioral Change and the Impact on Quality of Life in Elderly Patients with Advanced Cancer: A Physical Activity Intervention of the Multimodal Nutrition and Exercise Treatment for Advanced Cancer Program. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2018, 5, 383-390.	0.7	31
48	The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. <i>Annals of Oncology</i> , 2013, 24, 1653-1659.	0.6	30
49	Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. <i>Annals of Thoracic Medicine</i> , 2015, 10, 61-6.	0.7	30
50	L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. <i>Anticancer Research</i> , 2011, 31, 4075-82.	0.5	30
51	Lung Dendritic Cells Have a Potent Capability to Induce Production of Immunoglobulin A. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008, 38, 161-167.	1.4	28
52	Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. <i>Lung Cancer</i> , 2012, 76, 439-444.	0.9	28
53	&lt;p&gt;Emerging Treatment Options For Cancer-Associated Cachexia: A Literature Review&lt;/p&gt;. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 1253-1266.	0.9	28
54	The role of $\beta$ -tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. <i>International Journal of Clinical Oncology</i> , 2013, 18, 371-379.	1.0	27

#	ARTICLE	IF	CITATIONS
55	Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. <i>Neoplasma</i> , 2014, 61, 233-240.	0.7	27
56	Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. <i>BMC Cancer</i> , 2014, 14, 18.	1.1	27
57	Skeletal muscle loss and prognosis of breast cancer patients. <i>Supportive Care in Cancer</i> , 2017, 25, 2221-2227.	1.0	27
58	Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1052-1059.	1.0	27
59	<sup>18</sup> F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors. <i>Annals of Nuclear Medicine</i> , 2011, 25, 247-253.	1.2	26
60	Identification of actionable mutations in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2014, 86, 35-40.	0.9	26
61	Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy. <i>Journal of Cancer</i> , 2018, 9, 2054-2060.	1.2	26
62	Biological correlation of <sup>18</sup> F-FDG uptake on PET in pulmonary neuroendocrine tumors. <i>Anticancer Research</i> , 2013, 33, 4219-28.	0.5	26
63	Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy. <i>Oncotarget</i> , 2018, 9, 17664-17674.	0.8	25
64	Cardiac Dysfunction Caused by Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, e159-e160.	0.5	24
65	Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity. <i>Lung Cancer</i> , 2016, 99, 151-154.	0.9	23
66	ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature. <i>BMC Cancer</i> , 2017, 17, 471.	1.1	23
67	Evaluation of the True Endpoint of Clinical Trials for Cancer Cachexia. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2019, 6, 227-233.	0.7	23
68	Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2020, 38, 1612-1617.	1.2	23
69	Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 859-866.	0.6	23
70	Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100020.	0.6	23
71	CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma. <i>Tumor Biology</i> , 2018, 40, 101042831876042.	0.8	22
72	Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer. <i>Anticancer Research</i> , 2011, 31, 4519-23.	0.5	22

#	ARTICLE	IF	CITATIONS
73	Acute Lung Injury With Alveolar Hemorrhage As Adverse Drug Reaction Related to Crizotinib. <i>Journal of Clinical Oncology</i> , 2013, 31, e417-e419.	0.8	21
74	Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e405-e414.	1.1	21
75	Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. <i>Lung Cancer</i> , 2011, 74, 419-425.	0.9	20
76	Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2017, 22, 690-697.	1.0	20
77	Modified <scp>GAP</scp> index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non-small cell lung cancer. <i>Respirology</i> , 2017, 22, 1379-1385.	1.3	20
78	Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 247-256.	1.3	20
79	Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma. <i>Investigational New Drugs</i> , 2021, 39, 571-577.	1.2	20
80	Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors. <i>Oncology Reports</i> , 2011, 26, 931-7.	1.2	19
81	Impact of Cancer Cachexia on Hospitalization-associated Physical Inactivity in Elderly Patients with Advanced Non-small-cell Lung Cancer. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2018, 5, 377-382.	0.7	19
82	Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study. <i>PLoS ONE</i> , 2019, 14, e0210074.	1.1	19
83	Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression. <i>Lung Cancer</i> , 2021, 151, 60-68.	0.9	19
84	Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib. <i>Anticancer Research</i> , 2009, 29, 2747-51.	0.5	19
85	18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: A clinicopathological study. <i>European Journal of Radiology</i> , 2012, 81, 2423-2429.	1.2	18
86	Efficacy of Rechallenge Chemotherapy in Patients With Sensitive Relapsed Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 28-32.	0.6	18
87	A multicenter, open-label, single-arm study of anamorelin (ONO7643) in patients with cancer cachexia and low body mass index. <i>Cancer</i> , 2022, 128, 2025-2035.	2.0	18
88	Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. <i>Investigational New Drugs</i> , 2021, 39, 1716-1723.	1.2	17
89	N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases. <i>International Journal of Clinical Oncology</i> , 2010, 15, 484-488.	1.0	16
90	Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens. <i>International Journal of Clinical Oncology</i> , 2014, 19, 63-67.	1.0	16

#	ARTICLE	IF	CITATIONS
91	A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 840-843.	0.6	16
92	S-1 Treatment for Chemorefractory Thymic Carcinoma. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1076.	0.5	15
93	Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2010, 15, 161-165.	1.0	15
94	Expression of Excision Repair Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and $\beta$ -Tubulin in Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2011, 6, 606-613.	0.5	15
95	MUC1 Expression in Pulmonary Metastatic Tumors: A Comparison of Primary Lung Cancer. <i>Pathology and Oncology Research</i> , 2012, 18, 439-447.	0.9	15
96	Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. <i>Medical Oncology</i> , 2014, 31, 88.	1.2	15
97	Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 106, 138-144.	0.9	15
98	Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 609-614.	1.1	15
99	ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease. <i>Lung Cancer</i> , 2018, 121, 48-53.	0.9	15
100	Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence. <i>Anticancer Research</i> , 2011, 31, 3775-82.	0.5	15
101	Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer. <i>Anticancer Research</i> , 2014, 34, 1975-81.	0.5	15
102	Evaluation of the Safety and Compliance of 3-Week Cycles of Vinorelbine on Days 1 and 8 and Cisplatin on Day 1 as Adjuvant Chemotherapy in Japanese Patients with Completely Resected Pathological Stage IB to IIIA Non-small Cell Lung Cancer: A Retrospective Study. <i>Japanese Journal of Clinical Oncology</i> , 2008, 39, 158-162.	0.6	14
103	Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer. <i>Annals of Nuclear Medicine</i> , 2010, 24, 697-705.	1.2	14
104	The effects of advanced age and serum $\alpha$ -acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2416-2425.	1.1	14
105	PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 617-622.	0.6	14
106	CD98 expression is associated with the grade of malignancy in thymic epithelial tumors. <i>Oncology Reports</i> , 2010, 24, 861-7.	1.2	14
107	Dose-Escalation Study of Three-Dimensional Conformal Thoracic Radiotherapy With Concurrent S-1 and Cisplatin for Inoperable Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 440-445.	1.1	13
108	The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. <i>International Journal of Clinical Oncology</i> , 2015, 20, 668-673.	1.0	13



#	ARTICLE	IF	CITATIONS
109	Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer. <i>Cancer Science</i> , 2016, 107, 1018-1021.	1.7	13
110	The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1229-1237.	1.1	13
111	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. <i>Clinical Lung Cancer</i> , 2017, 18, 719-723.	1.1	13
112	Gefitinib-Induced Cardiomyopathy in Epidermal Growth Receptor-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, e207-e208.	0.5	13
113	Intestinal metastasis from non-small-cell lung cancer initially detected by 18F-fluorodeoxyglucose positron emission tomography. <i>Japanese Journal of Radiology</i> , 2010, 28, 684-687.	1.0	12
114	Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1493-1498.	1.1	12
115	Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 128, 152-157.	0.9	12
116	Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitis. <i>Anticancer Research</i> , 2012, 32, 1811-6.	0.5	11
117	Disease flare after gefitinib discontinuation. <i>Respiratory Investigation</i> , 2015, 53, 68-72.	0.9	10
118	Proposing synchronous oligometastatic non-small cell lung cancer based on progression after first-line systemic therapy. <i>Cancer Science</i> , 2021, 112, 359-368.	1.7	10
119	Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2022, 40, 403-410.	1.2	10
120	Evaluation of the efficacy and safety of chemotherapy for patients with wet stage IIIB/IV non-small-cell lung cancer aged 80 years old or more. <i>Lung Cancer</i> , 2011, 71, 173-177.	0.9	9
121	Efficacy and Safety of Platinum Combination Chemotherapy Re-Challenge for Relapsed Patients with Non-Small-Cell Lung Cancer after Postoperative Adjuvant Chemotherapy of Cisplatin plus Vinorelbine. <i>Chemotherapy</i> , 2013, 59, 307-313.	0.8	9
122	Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors. <i>Cancer Science</i> , 2013, 104, 1039-1044.	1.7	9
123	Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 6, 718-722.	0.4	9
124	Efficacy of daikenchuto, a traditional Japanese Kampo medicine, for postoperative intestinal dysfunction in patients with gastrointestinal cancers: meta-analysis. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1385-1396.	1.0	9
125	Barriers in Nursing Practice in Cancer Cachexia: A Scoping Review. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 498-507.	0.7	9
126	Reactive Legionella pneumophila arthritis diagnosed by polymerase chain reaction. <i>Rheumatology International</i> , 2007, 27, 415-416.	1.5	8



#	ARTICLE	IF	CITATIONS
127	Toxicity and efficacy of chemotherapy for non-small cell lung cancer with cavitory lesions. <i>Respiratory Investigation</i> , 2014, 52, 184-189.	0.9	8
128	The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients. <i>Investigational New Drugs</i> , 2015, 33, 755-760.	1.2	8
129	Negative impact of leukoaraiosis on the incidence of brain metastases in patients with lung cancer. <i>Journal of Neuro-Oncology</i> , 2017, 135, 299-306.	1.4	8
130	Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer. <i>Anticancer Research</i> , 2012, 32, 675-80.	0.5	8
131	Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: A retrospective study in Japan. <i>Respiratory Investigation</i> , 2012, 50, 157-161.	0.9	7
132	Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 859-865.	1.1	7
133	Perianal Metastasis of Non-Small Cell Lung Cancer. <i>Internal Medicine</i> , 2014, 53, 1149-1152.	0.3	7
134	Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy. <i>SpringerPlus</i> , 2015, 4, 152.	1.2	7
135	Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy. <i>Molecular and Clinical Oncology</i> , 2016, 5, 575-578.	0.4	7
136	Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer. <i>In Vivo</i> , 2019, 33, 2229-2234.	0.6	7
137	Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance Status. <i>Nutrition and Cancer</i> , 2019, 71, 767-771.	0.9	7
138	Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities. <i>Radiation Oncology</i> , 2021, 16, 52.	1.2	7
139	Impact of losing adipose tissue on outcomes from $PD-1$ inhibitor monotherapy in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 1496-1504.	0.8	7
140	Predicting the efficacy of $first\ line$ immunotherapy by combining cancer cachexia and tumor burden in advanced $non\ small\ cell$ lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2064-2074.	0.8	7
141	Chemoradiotherapy for Limited-disease Small-cell Lung Cancer in Elderly Patients Aged 75 Years or Older. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 176-183.	0.6	6
142	Outcome of platinum-based chemotherapy for non-small-cell lung cancer patients with pleural dissemination detected during surgery. <i>Molecular and Clinical Oncology</i> , 2013, 1, 949-952.	0.4	6
143	Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients. <i>Respiratory Investigation</i> , 2014, 52, 101-106.	0.9	6
144	Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy. <i>Radiology and Oncology</i> , 2015, 49, 409-415.	0.6	6

#	ARTICLE	IF	CITATIONS
145	Primary malignant melanoma of the trachea: A case report. <i>Oncology Letters</i> , 2015, 9, 657-660.	0.8	6
146	Characterization of tumour mutation burden in patients with non-small cell lung cancer and interstitial lung disease. <i>Respirology</i> , 2020, 25, 850-854.	1.3	6
147	Development of home-based resistance training for older patients with advanced cancer: The exercise component of the nutrition and exercise treatment for advanced cancer program. <i>Journal of Geriatric Oncology</i> , 2021, 12, 952-955.	0.5	6
148	Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer. <i>Supportive Care in Cancer</i> , 2022, 30, 1633-1641.	1.0	6
149	Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation. <i>Anticancer Research</i> , 2013, 33, 3279-84.	0.5	6
150	Thymic squamous cell carcinoma producing granulocyte colony-stimulating factor associated with a high serum level of interleukin 6. <i>International Journal of Clinical Oncology</i> , 2009, 14, 534-536.	1.0	5
151	Phase I Results of Vinorelbine With Concurrent Radiotherapy in Elderly Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI). <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1777-1782.	0.4	5
152	Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy. <i>Respiratory Investigation</i> , 2014, 52, 121-128.	0.9	5
153	18F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms. <i>Oncology Reports</i> , 2014, 31, 209-215.	1.2	5
154	Characteristics of cellular composition in malignant pericardial effusion and its association with the clinical course of carcinomatous pericarditis. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 291-294.	0.6	5
155	Crizotinib-induced simultaneous multiple cardiac toxicities. <i>Investigational New Drugs</i> , 2018, 36, 949-951.	1.2	5
156	Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 1463-1468.	0.5	5
157	Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation. <i>Investigational New Drugs</i> , 2020, 38, 194-201.	1.2	5
158	Nursing Management of Cancer Cachexia: A New Frontier. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 442-444.	0.7	5
159	Management of anorexia prevents skeletal muscle wasting during cisplatin-based chemotherapy for thoracic malignancies. <i>JCSM Clinical Reports</i> , 2020, 5, 8-15.	0.5	5
160	Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis. <i>Investigational New Drugs</i> , 2022, 40, 411-419.	1.2	5
161	Efficacy of a consensus protocol therapy in adults with acute, severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2003, 90, 331-337.	0.5	4
162	18F-FDG uptake on PET could be a predictive marker of Excision Repair Cross-Complementation Group 1 (ERCC1) expression in patients with thoracic neoplasms?. <i>Neoplasma</i> , 2012, 59, 257-263.	0.7	4

#	ARTICLE	IF	CITATIONS
163	Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein. <i>Investigational New Drugs</i> , 2019, 37, 184-187.	1.2	4
164	Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation. <i>Cancer Medicine</i> , 2021, 10, 7503-7513.	1.3	4
165	Phase 1b study of ramucirumab in combination with irinotecan plus cisplatin in chemo-naïve patients with extensive-stage small-cell lung cancer. <i>Lung Cancer</i> , 2022, 164, 39-45.	0.9	4
166	Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 115-123.	1.1	4
167	Well-differentiated Hepatocellular Carcinoma Showing Intrahepatic Neural Invasion: Autopsied Case. <i>Japanese Journal of Clinical Oncology</i> , 1991, 21, 143-146.	0.6	3
168	Thenar muscle metastasis as recurrence of pulmonary squamous cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 15-16.	0.7	3
169	Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2014, 86, 339-343.	0.9	3
170	Differences in the efficacy of EGFR monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 121-125.	0.8	3
171	Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing. <i>Clinical Lung Cancer</i> , 2017, 18, 519-526.e1.	1.1	3
172	Acquired immunodeficiency associated with thymoma: a case report. <i>BMC Cancer</i> , 2019, 19, 762.	1.1	3
173	Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 605-614.	1.1	3
174	Impact of Physical Inactivity on the Risk of Disability and Hospitalization in Older Patients with Advanced Lung Cancer. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 1521-1532.	1.1	3
175	Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2455-2463.	1.2	3
176	The impact of steroid use on efficacy of immunotherapy among patients with lung cancer who have developed immune-related adverse events. <i>Journal of Clinical Oncology</i> , 2019, 37, e20583-e20583.	0.8	3
177	Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2021, 21, 1247.	1.1	3
178	Papillary Squamous Cell Carcinoma of the Trachea Associated with Human Papillomavirus-18 Infection. <i>Internal Medicine</i> , 2013, 52, 2785-2788.	0.3	2
179	Tracheal granuloma 7 years after extubation. <i>Respirology Case Reports</i> , 2017, 5, e00252.	0.3	2
180	Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials. <i>British Journal of Cancer</i> , 2018, 118, 1571-1579.	2.9	2

#	ARTICLE	IF	CITATIONS
181	Clinical impact of walking capacity on the risk of disability and hospitalizations among elderly patients with advanced lung cancer. <i>Supportive Care in Cancer</i> , 2021, 29, 3961-3970.	1.0	2
182	Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis. <i>Investigational New Drugs</i> , 2021, 39, 1732-1741.	1.2	2
183	Identification of actionable mutations in surgically resected tumor specimens from Japanese patients with non-small cell lung cancer by ultra-deep targeted sequencing. <i>Journal of Clinical Oncology</i> , 2013, 31, 7572-7572.	0.8	2
184	Changes in TROP2 expression in lung cancer patients receiving anticancer treatments. <i>Journal of Clinical Oncology</i> , 2019, 37, e14732-e14732.	0.8	2
185	Lymphangitis Carcinomatosa as a Potential Predictor for a Response to Gefitinib. <i>Clinical Oncology</i> , 2006, 18, 573-574.	0.6	1
186	Differential efficacy of docetaxel according to non-small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors. <i>Oncology Letters</i> , 2011, 2, 1059-1064.	0.8	1
187	A multicenter, open-label, uncontrolled study of ONO-7643/anamorelin in cachexia patients with gastrointestinal cancer. <i>Annals of Oncology</i> , 2018, 29, vii50.	0.6	1
188	Efficacy of second-line chemotherapy in poor-risk patients with refractory-relapsed small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 822-826.	0.6	1
189	Pseudo-Meigs's syndrome. <i>BMJ Case Reports</i> , 2021, 14, e241337.	0.2	1
190	Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 659-669.	1.0	1
191	Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1736-1743.	0.6	1
192	Clinical impact of tumour burden on the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy in non-small cell lung cancer. <i>Cancer Medicine</i> , 0, , .	1.3	1
193	CD98 expression is associated with the grade of malignancy in thymic epithelial tumors. <i>Oncology Reports</i> , 2010, , .	1.2	0
194	260 Deformability-based Isolation of Circulating Tumor Cells in Lung Cancer Patients with Microcavity Array System. <i>European Journal of Cancer</i> , 2012, 48, 80.	1.3	0
195	Prognostic Impact of Serum Cyfra 21-1 In Advanced Lung Adenocarcinoma. <i>Annals of Oncology</i> , 2012, 23, ix430.	0.6	0
196	Molecular Targeting Therapy and Csf Shunt for Patients with Leptomeningeal Metastasis From Lung Adenocarcinoma. <i>Annals of Oncology</i> , 2014, 25, v70.	0.6	0
197	Comparison of the Radiotherapeutic Efficacy in Nscl with Postoperative Mediastinal Lymph Nodes Recurrence and Stage Iii. <i>Annals of Oncology</i> , 2014, 25, v94.	0.6	0
198	Comparison of platinum rechallenge and docetaxel in non-small cell lung cancer previously treated with chemoradiotherapy. <i>Annals of Oncology</i> , 2015, 26, vii123.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Antihypertensive therapy of bevacizumab-induced hypertension. <i>Annals of Oncology</i> , 2015, 26, vii131.	0.6	0
200	The role of exercise intervention in the management of cancer cachexia. <i>Annals of Oncology</i> , 2015, 26, vii46.	0.6	0
201	Progress in multimodal intervention for cancer cachexia. <i>Annals of Oncology</i> , 2017, 28, ix40.	0.6	0
202	A Patient with a Massive Single Cardiac Metastasis of Lung Adenocarcinoma, Diagnosed via a Biopsy. <i>Internal Medicine</i> , 2018, 57, 1637-1640.	0.3	0
203	Development of Low-intensity Home-based Resistance Training for Elderly Patients with Advanced Cancer: The Exercise Component of the NEXTAC Program. <i>Palliative Care Research</i> , 2018, 13, 373-381.	0.0	0
204	PD-L1 Expression and Response to Pembrolizumab in Japanese Patients with EGFR-Mutant Non-small Cell Lung Cancer. <i>Annals of Oncology</i> , 2019, 30, vi112-vi113.	0.6	0
205	Risk of Ischemic Heart Disease in Patients After Concurrent Chemoradiotherapy for Lung and Esophageal Cancer: A Case-Control Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, E507-E508.	0.4	0
206	Foreign Body Impaction in the Esophagus. <i>Mayo Clinic Proceedings</i> , 2019, 94, 923.	1.4	0
207	Days Spent at Home near the End of Life in Japanese Elderly Patients with Lung Cancer: Post hoc Analysis of a Prospective Study. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 228.	0.7	0
208	Impact of prior ALK-tyrosine kinase inhibitor on pemetrexed-based chemotherapy in patients with advanced ALK positive non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21113-e21113.	0.8	0
209	MO21-1 Prognostic value of pneumonitis after durvalumab in locally-advanced non-small cell lung cancer. <i>Annals of Oncology</i> , 2021, 32, S311.	0.6	0
210	Challenges in enhancing physical performance in thoracic cancer cachexia. <i>Thoracic Cancer</i> , 2021, 12, 2633-2634.	0.8	0
211	Multimutational profiling of rebiopsy samples from NSCLC developing acquired resistance to EGFR-TKI in Japanese patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19032-e19032.	0.8	0
212	Osimertinib for pretreated epidermal growth factor receptor Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. <i>Translational Cancer Research</i> , 2017, 6, S235-S238.	0.4	0
213	Long-term clinical outcomes of ALK inhibitors in patients with ALK-positive advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20542-e20542.	0.8	0
214	A randomized phase II study of the nutritional and exercise treatment for the elderly patients with advanced non-small cell lung or pancreatic cancer: The NEXTAC-TWO study.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS10131-TPS10131.	0.8	0
215	Optimal treatment sequence for untreated EGFR-mutant NSCLC with brain metastases.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14021-e14021.	0.8	0
216	Abstract 4606: Subclassification of patients with lung adenocarcinoma harboring EGFR-activating mutations by gene expression profiling. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
217	A modified ILD-GAP index for patients with non-small cell lung cancer and interstitial lung disease. , 2018, , .		0
218	Impact of baseline number of metastases on the efficacy of PD-1 inhibitor monotherapy for non-small cell lung cancer with high PD-L1 expression.. Journal of Clinical Oncology, 2019, 37, e20551-e20551.	0.8	0
219	Development of the Early Nutritional Intervention for Elderly Patients with Advanced Cancer: Details of Nutritional Intervention in the Multimodal NEXTAC-ONE Program. Palliative Care Research, 2020, 15, 71-80.	0.0	0
220	Barriers in Nursing Practice in Cancer Cachexia: A Scoping Review. Asia-Pacific Journal of Oncology Nursing, 2021, 8, 498-507.	0.7	0
221	Abstract 735: Squamous cell lung cancer with interstitial lung disease has low tumor mutation burden. , 2019, , .		0